Background/Aim: We evaluated the clinical outcomes of patients with metastatic germ cell tumors (GCT) treated at our hospital, which belongs to a regional cancer center. Patients and Methods: Data pertaining to patients with metastatic GCT were obtained between April 2007-October 2017 and was retrospectively analyzed. Key outcome measures included objective response rates and survival rates. Results: All 42 patients received chemotherapy [complete response: eight (19.0%); partial response: 21 (50.0%); stable disease (SD): nine (21.4%); progressive disease: four patients (9.5%)]. Post-chemotherapeutic surgery was performed for seven out of 21 cases of partial response and two out of nine of stable disease. The 5-year survival rates of patients with good, intermediate and poor prognosis (International Germ Cell Consensus Classification) were 100%, 100%, and 71.4%, respectively. Patients who received induction chemotherapy at other hospitals had significantly poorer prognosis than those at our hospital (p=0.0043). Conclusion: Patients with metastatic GCT should preferably receive chemotherapy at an experienced institution. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: We evaluated the clinical outcomes of patients with metastatic germ cell tumors (GCT) treated at our hospital, which belongs to a regional cancer center. Patients and Methods: Data pertaining to patients with metastatic GCT were obtained between April 2007-October 2017 and was retrospectively analyzed. Key outcome measures included objective response rates and survival rates. Results: All 42 patients received chemotherapy [complete response: eight (19.0%); partial response: 21 (50.0%); stable disease (SD): nine (21.4%); progressive disease: four patients (9.5%)]. Post-chemotherapeutic surgery was performed for seven out of 21 cases of partial response and two out of nine of stable disease. The 5-year survival rates of patients with good, intermediate and poor prognosis (International Germ Cell Consensus Classification) were 100%, 100%, and 71.4%, respectively. Patients who received induction chemotherapy at other hospitals had significantly poorer prognosis than those at our hospital (p=0.0043). Conclusion: Patients with metastatic GCT should preferably receive chemotherapy at an experienced institution. Copyright 2021, International Institute of Anticancer Research.
Authors: Stephen D W Beck; Richard S Foster; Richard Bihrle; Lawrence H Einhorn; John P Donohue Journal: Urol Oncol Date: 2005 Nov-Dec Impact factor: 3.498
Authors: Klaus-Peter Dieckmann; Arlo Radtke; Meike Spiekermann; Thomas Balks; Cord Matthies; Pascal Becker; Christian Ruf; Christoph Oing; Karin Oechsle; Carsten Bokemeyer; Johannes Hammel; Sebastian Melchior; Werner Wosniok; Gazanfer Belge Journal: Eur Urol Date: 2016-08-02 Impact factor: 20.096
Authors: C Albany; N Adra; A C Snavely; C Cary; T A Masterson; R S Foster; K Kesler; T M Ulbright; L Cheng; M Chovanec; F Taza; K Ku; M J Brames; N H Hanna; L H Einhorn Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ricardo Leão; Ton van Agthoven; Arnaldo Figueiredo; Michael A S Jewett; Kamel Fadaak; Joan Sweet; Ardalan E Ahmad; Lynn Anson-Cartwright; Peter Chung; Aaron Hansen; Padraig Warde; Pedro Castelo-Branco; Martin O'Malley; Philippe L Bedard; Leendert H J Looijenga; Robert J Hamilton Journal: J Urol Date: 2018-02-21 Impact factor: 7.450